Cory Renauer is a Healthcare Analyst/Contract Writer at various publications. He specializes in writing about investing in healthcare and fintech stocks, with a focus on finance, trading, and the intersections of medicine and healthcare. Cory's work has been featured in BioSpace, Yahoo Finance, Nasdaq, The Motley Fool, and other notable outlets.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Cory's articles primarily focus on investment analysis, with a particular emphasis on healthcare and pharmaceutical companies, as well as high-yield dividend stocks. He also covers stock market trends and specific stock recommendations based on data-driven analyses.
For effective outreach to Cory Renauer, consider providing data-backed insights into the performance of healthcare and pharmaceutical companies or high-yield dividend stocks. If you have expertise in analyzing investment opportunities within these sectors, particularly with reference to specific stocks or broader market trends, your pitch is likely to be well-received.
It's important that any information provided is backed by credible data and rigorous analysis given Cory's strong reliance on cited data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Cory Renauer
Key Points Whether you want passive income or not, dividend-paying stocks tend to outperform their non-dividend-paying cousins. Coca-Cola and Amgen offer dividend yields above 3% at recent prices. Amgen has raised its dividend payout for 12 consecutive years, and Coca-Cola's streak has been running for 62 years. Buy Alert: Our 10 best stocks to buy right now (see the list)
By: Cory Renauer
Coca-Cola (NYSE: KO) and Sirius XM (NASDAQ: SIRI) don't compete in the same industry, but dividend-seeking investors can find reasons to appreciate both stocks. Coca-Cola attracts income-seeking investors with leading brands and a 62-year annual dividend-raising steak. What Sirius XM's dividend program lacks in longevity it makes up for with rapid payout bumps.
Key Points From the end of June through Dec. 10, shares of SoFi Technologies shot 131% higher. The number of financial service products SoFi Technologies manages has nearly doubled over the past two years. A Bank of America analyst recently downgraded the stock to underperform.
By: Cory Renauer
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
By: Cory Renauer
Key Points Shares of uniQure have more than doubled in December. The company is developing a gene therapy to treat Huntington's disease called AMT-130. UniQure recently said the Food and Drug Administration will consider an application for AMT-130 much earlier than investors had expected. Motley Fool Issues Rare “All In” Buy Alert
By: Cory Renauer
Key Points Viking Therapeutics stock has risen about 157% in 2024. Summit Therapeutics stock has gained about 583% in 2024. Wall Street analysts who follow Viking and Summit expect further gains in 2025. Motley Fool Issues Rare “All In” Buy Alert
By: Cory Renauer
Key Points Warren Buffett's holding company trimmed its stake in Bank of America, but it's still the third largest holding in Berkshire Hathaway's equity portfolio. Bank of America has benefitted from a high-interest-rate environment. Bank of America's conservative behavior caused it to miss a big opportunity that JPMorgan Chase pounced on.
By: Cory Renauer
Key Points CRISPR Therapeutics stock is way down in 2024, but Wall Street analysts expect a rebound in 2025. Sales of Iovance Biotherapeutics' first FDA-approved treatment are soaring, but the drugmaker still sports a modest valuation. 10 stocks we like better than CRISPR Therapeutics
By: Cory Renauer
Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking presentation. In response to Pfizer's latest guidance update, BMO Capital analyst Evan Seigerman reiterated an outperform rating and a $36 per-share price target. If Pfizer stock reaches Seigerman's target, investors who buy at recent prices could see their principal investments gain about 37% in the year ahead.
By: Cory Renauer
Key Points At their current share prices, Verizon and Chevron offer dividend yields that are more than twice the average yield of dividend-paying stocks in the Dow Jones Industrial Average index. Verizon's yield is above 6%, but an upcoming acquisition could make it harder for the telecom giant to maintain its dividend payments. Chevron's yield is above 4%, and it has a 37-year dividend-raising streak. Motley Fool Issues Rare “All In” Buy Alert
(833) 317-6278 
